Why has CIR just paid out for two new analyst reports? No new...

Why has CIR just paid out for two new analyst reports?
No new capital raising on the cards that I can see.
A deal on VGX-100 is not expected until 2013 at the earliest, post the Phase 1 clinical trials.
Are they just trying to prop up the share price to discourage any potential takeovers? Surely anyone serious about a TO would see the difference in price as small change?
All seems very mysterious to me - but then I am suspicious by nature.

Or am I just reading this wrong that Circadian commissioned the reports? If that is the case the increased interest can only be good news...